arrow
D

Declan G. Murphy

Peter MacCallum Cancer Centre
H指数:68
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Oligometastatic prostate cancer in the PSMA PET era: a state-specific narrative review of emerging therapeutic strategies

寡转移性前列腺癌在PSMA PET时代:一种基于特定治疗阶段的叙事性综述新兴治疗策略

2026-10-230
OAAI
Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era

PSMA-PET时代原发miN1前列腺癌的管理

2026-09-290
OAAI
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma

动态免疫特征分析预测寡转移性肾细胞癌对放疗联合抗PD-1疗法的反应

2026-07-080
OAAI
Delphi consensus on ex vivo fluorescence confocal microscopy in robot-assisted radical prostatectomy

关于机器人辅助根治性前列腺切除术术中应用离体荧光共聚焦显微镜的德尔菲共识

2026-06-100
PRE
γδ T cell-derived IL-4 initiates CD8+ T cell immunity

Γ δ T细胞源性IL-4启动CD8 T细胞免疫

2026-01-300
OAAI
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis

转移性去势抵抗性前列腺癌患者中初始影像和PSA变化对[177Lu]Lu-PSMA-617放射性药物治疗的预后价值:一项ProsTIC登记研究分析

2025-12-011
PRE
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis

DARolutamide观察性(DAROL)研究:非转移性去势抵抗性前列腺癌患者的预先设定第三次中期分析

2025-11-010
OA
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

镥-177 [177Lu]Lu-PSMA-I&T 联合镭-223 治疗转移性去势抵抗性前列腺癌(AlphaBet 研究):一项研究者发起、单中心、单臂、Ⅰ/Ⅱ期试验的期中分析

2025-10-180
PRE
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis

SPARC:标准化前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描分析与报告共识:一项德尔菲分析

2025-09-130
PREAI